(PharmaNewsWire.Com, August 27, 2019 ) The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.
On the basis of application, the digital therapeutics market is segmented into preventive and treatment/care-based applications. On the basis of sales channel, the digital therapeutics market is segmented into B2C and B2B sales channel. The B2B segment is estimated to command the largest share in 2016 and register the highest CAGR in the digital therapeutics market, by sales channel. Factors such as growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug products are driving the growth of this segment.
Based on geography, the global digital therapeutics market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors, including growing incidence of chronic diseases, government initiatives to support technological advancements in the field of digital therapeutics, and a growing influx of new startup companies in the market.
Prominent players in the digital therapeutics market include Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), and Mango Health, Inc. (U.S.).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
